Efexor


Also found in: Dictionary, Wikipedia.
Related to Efexor: Wellbutrin

venlafaxine hydrochloride

Co Venlafaxine, Co Venlafaxine XR, Efexor (UK), Effexor, Effexor XR, Gen-Venlafaxine XR, Novo-Venlafaxine XR, PMS-Venlafaxine XR, Ratio-Venlafaxine XR, Riva-Venlafaxine XR, Sandoz Venlafaxine XR

Pharmacologic class: Phenethylamine derivative

Therapeutic class: Antidepressant, anxiolytic

Pregnancy risk category C

Action

Inhibits neuronal serotonin and norepinephrine reuptake and slightly inhibits dopamine reuptake

Availability

Capsules (extended-release): 37.5 mg, 75 mg, 150 mg

Tablets: 25 mg, 37.5 mg, 50 mg, 75 mg, 100 mg

Tablets (extended-release): 37.5 mg, 75 mg, 150 mg, 225 mg

Indications and dosages

Depression

Adults: In outpatients, 75 mg P.O. daily in two or three divided doses; may increase in increments of 75 mg/day q 4 or more days to a maximum of 225 mg/day; extended-release form can be given as a single daily dose. In hospitalized patients, 75 mg P.O. daily in two or three divided doses; may increase in increments of 75 mg/day q 4 days to a maximum of 375 mg/day given in three divided doses.

Generalized anxiety disorder

Adults: Single dose of 37.5 to 75 mg (extended-release) P.O. daily; may increase in increments of 75 mg/day q 4 days to a maximum of 225 mg/day

Panic disorder

Adults: 37.5 mg (extended-release) P.O. daily for 7 days; increase to 75 mg P.O. daily for 7 days; then increase by 75 mg daily at weekly intervals to a maximum of 225 mg P.O. daily

Social anxiety disorder

Adults: 75 mg (extended-release capsule) P.O. daily as a single dose

Dosage adjustment

• Hepatic or renal impairment

Off-label uses

• Premenstrual dysphoric disorder

Contraindications

• Hypersensitivity to drug
• MAO inhibitor use within past 14 days

Precautions

Use cautiously in:
• cardiovascular disease; hypertension; heart failure, recent myocardial infarction, and other conditions in which increased heart rate poses a danger; hepatic or renal impairment; glaucoma; hyperthyroidism; hyponatremia; syndrome of inappropriate antidiuretic hormone secretion (SIADH)
• history of seizures, neurologic impairment, or drug abuse
• pregnant or breastfeeding patients
• children younger than age 18.

Administration

Don't give within 14 days of MAO inhibitors.

Adverse reactions

CNS: abnormal dreams, anxiety, dizziness, headache, insomnia, nervousness, abnormal thinking, agitation, confusion, depersonalization, drowsiness, emotional lability, worsening depression, twitching, tremor, asthenia, paresthesia, mania, hypomania, suicidal ideation or behavior (especially in child or adolescent)

CV: chest pain, hypertension, palpitations, tachycardia, vasodilation

EENT: visual disturbances, blurred vision, mydriasis, tinnitus, rhinitis

GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, flatulence, dry mouth, anorexia

GU: urinary frequency or retention, sexual dysfunction, abnormal ejaculation, anorgasmia, erectile dysfunction

Metabolic: hyponatremia, SIADH

Skin: bruising, pruritus, rash, diaphoresis, photosensitivity

Other: altered taste, weight loss, chills, yawning

Interactions

Drug-drug.Cimetidine: increased venlafaxine effects

MAO inhibitors: potentially fatal reactions

Sumatriptan, trazodone: serotonin syndrome (including altered level of consciousness)

Drug-diagnostic tests.Sodium: decreased level

Drug-herbs.Chamomile, hops, kava, skullcap, valerian: increased CNS depression

S-adenosylmethionine (SAM-e), St. John's wort: increased risk of sedative or hypnotic effects

Patient monitoring

Monitor neurologic status, particularly for seizures, worsening depression, and suicidal ideation.
• Closely monitor vital signs and cardiovascular status. Stay alert for hypertension and tachycardia.
• Monitor nutritional status, hydration, and weight.

Patient teaching

• Tell patient taking extended-release capsules to swallow them whole without chewing, breaking, dividing, or dissolving.

Caution patient not to stop therapy abruptly.

Advise patient to promptly report seizures, worsening depression, or suicidal thoughts (especially in child or adolescent).
• Caution patient to avoid driving and other dangerous activities until drug effects are known.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

Efexor

A brand name for VENLAFAXINE.
References in periodicals archive ?
Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today affirms the safety and efficacy of EFEXOR(R) (venlafaxine HCl) and EFEXOR XL(R) (venlafaxine HCl sustained release), (collectively EFEXOR), and disagrees with the United Kingdom's (UK) Medicine and Healthcare Products Regulatory Agency's (MHRA) decision to require interim measures that would restrict access to these treatments.
Wyeth's most recent review of preclinical and clinical data, and 10 years of post-marketing experience with more than 10 million patients, confirm the safety and efficacy of EFEXOR for the treatment of depression and anxiety," says Gary L.
Mental health campaigners yesterday voiced 'deep concern' over a widely-used class of antidepressant drugs after medical authorities said the treatment Efexor should not be given to under-18s.
The Medicines and Healthcare products Regulatory Agency said anti-depressant Efexor should not be prescribed for children after research showed it provoked hostile behaviour and had no significant benefits.
Wyeth Pharmaceuticals, a division of Wyeth , today affirms the safety and efficacy of EFEXOR(R) (venlafaxine HCl) and EFEXOR XL(R) (venlafaxine HCl sustained release), (collectively EFEXOR), and disagrees with the United Kingdom's (UK) Medicine and Healthcare Products Regulatory Agency's (MHRA) decision to require interim measures that would restrict access to these treatments.
Seroxat (paroxetine), Prozac (fluoxetine),Lustral (sertraline), Edronax (reboxetine), Efexor (Venlafaxine)
In September the SSRI Efexor (venflaxine) was banned for use in under-18s.
Like Seroxat and Efexor, none of these drugs has ever been licensed for use in those under 18.
Privately held Neopharm is one of Israel's leading pharmaceutical companies, and currently distributes products for a number of multinational drug companies in Israel including Immunex (Enbrel), Pfizer (Lipitor, Neurontin), Takeda (Zoton) and Wyeth (Concor, Efexor, Novatrone, Zocin).
His efforts resulted in 20 NCEs being advanced into development, 12 INDs and 4 NDAs (including Efexor, Lodine, Durapro & Oruvail).
subsidiary of American Home Products Corporation (NYSE: AHP), announced today that the Italian Government has cleared EFEXOR (venlafaxine HCl) tablets for marketing.
A new, structurally novel antidepressant, EFEXOR is a serotonin and norepinephrine reuptake inhibitor.